FDA Approves Corcept's Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer
cept Therapeutics rporatedcept Therapeutics rporated(US:CORT) Businesswire·2026-03-26 00:43

公司动态 - 公司Corcept Therapeutics Incorporated宣布其药物Lifyorliâ"¢ (relacorilant)联合白蛋白结合型紫杉醇获得美国FDA批准，用于治疗铂类耐药的上皮性卵巢癌成年患者 [1] - 公司是一家处于商业化阶段的生物制药公司，致力于通过调节激素皮质醇的作用来发现和开发治疗严重内分泌、肿瘤、代谢和神经系统疾病的药物 [1] 产品与研发 - 新获批的药物Lifyorliâ"™ (relacorilant)是一种皮质醇调节剂 [1] - 该药物的获批适应症为与白蛋白结合型紫杉醇联合使用，治疗特定类型的卵巢癌（铂类耐药的上皮性卵巢癌）[1]

cept Therapeutics rporated-FDA Approves Corcept's Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer - Reportify